Blog
RSS FeedPosted by Michael Wonder on 27 Nov 2024
Lilly Canada remains steadfast in commitment to access options for patients amidst controversial CDA-AMC recommendation for Ebglyss (lebrikizumab)
19 November 2024 - Eli Lilly Canada is disappointed and strongly disagrees with Canada's Drug Agency (CDA-AMC)'s Final Recommendation for Ebglyss ...
Posted by Michael Wonder on 16 Nov 2024
Novartis Canada disappointed with outcome of pCPA negotiations for metastatic castration resistant prostate cancer treatment Pluvicto
15 November 2024 - Novartis Canada is extremely disappointed that negotiations for Pluvicto (lutetium (Lu 177 ) vipivotide tetraxetan injection), ...
Posted by Michael Wonder on 15 Nov 2024
Knight Therapeutics announces Health Canada approval for Jornay PM to treat attention deficit hyperactivity disorder
14 November 2024 - Knight Therapeutics announced today that Health Canada has approved Jornay PM, an extended-release formulation of methylphenidate, a ...
Posted by Michael Wonder on 13 Nov 2024
Ojjaara (momelotinib) approved in Canada for the treatment of myelofibrosis in adults who have moderate to severe anaemia
12 November 2024 - Ojjaara (momelotinib) is the only approved treatment for newly diagnosed and previously treated myelofibrosis patients who have ...
Posted by Michael Wonder on 09 Nov 2024
Moderna receives Health Canada approval for RSV vaccine for adults aged 60 years and older
8 November 2024 - mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only ...
Posted by Michael Wonder on 09 Nov 2024
Canada's Drug Agency recommends Winrevair (sotatercept) for reimbursement
8 November 2024 - Merck announced that Canada's Drug Agency has recommended Winrevair (sotatercept) for reimbursement in combination with standard ...
Posted by Michael Wonder on 06 Nov 2024
Expanded age indication for GSK's Arexvy, the first respiratory syncytial virus vaccine approved in Canada for adults aged 50-59 at increased risk
5 November 2024 - Clinical development program continues to evaluate safety and immunogenicity in adults aged 18-49 at increased risk ...
Posted by Michael Wonder on 04 Nov 2024
NS parents dismayed by lack of access to new RSV vaccines for infants
3 November 2024 - Officials say there is no universally available, publicly funded RSV vaccine program for newborns in Nova Scotia. ...
Posted by Michael Wonder on 01 Nov 2024
Differences in drug shortages in the US and Canada
31 October 2024 - In this cross-sectional study, there were 104 reports of drug-related supply chain issues that occurred from 2017 ...
Posted by Michael Wonder on 30 Oct 2024
Lilly Canada and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Verzenio (abemaciclib) in expanded early breast cancer indication
29 October 2024 - Eli Lilly Canada is pleased to announce that it received a positive Canada's Drug Agency (CDA-AMC, formally ...
Posted by Michael Wonder on 29 Oct 2024
Breast Cancer Canada 'Progress Report' reveals major gaps in screening and treatment delays across Canada
28 October 2024 - Breast Cancer Canada has released the 2024 Progress Report on Breast Cancer in Canada. ...
Posted by Michael Wonder on 24 Oct 2024
Canada’s Drug Agency announces recipients of funding to enhance rare disease registries
21 October 2024 - Canada’s Drug Agency is pleased to announce the successful applicants from our 2024 Request for Proposals (RFP) ...
Posted by Michael Wonder on 23 Oct 2024
Health Canada approves first and only oral targeted treatment for brain cancer
22 October 2024 - Pivotal Phase 3 study shows significant improvement in progression-free survival with a favourable safety profile. ...
Posted by Michael Wonder on 22 Oct 2024
Nine provinces approve accelerated public reimbursement of diffuse large B-cell lymphoma treatment under new early access process
21 October 2024 - AbbVie today announced that nine provinces have provided accelerated public coverage of Epkinly. ...
Posted by Michael Wonder on 19 Oct 2024
Arcutis announces Health Canada approval of Zoryve (roflumilast) foam 0.3% to treat seborrheic dermatitis in individuals 9 years of age and older
18 October 2024 - Zoryve foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved ...